{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:45:17Z","timestamp":1791999917197,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.dmd.2026.100363","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:00:19Z","timestamp":1783627219000},"page":"100363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["PSMD2 mediates the degradation of CYP1A2 and promotes the progression of metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1016","volume":"54","author":[{"given":"Min","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiye","family":"Aa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2991-6763","authenticated-orcid":false,"given":"Yuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dmd.2026.100363_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/metabo14010012","article-title":"Lipid metabolism in metabolic-associated steatotic liver disease (MASLD)","volume":"14","author":"Syed-Abdul","year":"2023","journal-title":"Metabolites"},{"issue":"1","key":"10.1016\/j.dmd.2026.100363_bib2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gutjnl-2024-332398","article-title":"Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma","volume":"74","author":"Ha","year":"2024","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.dmd.2026.100363_bib3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","article-title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"24","author":"Do","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.dmd.2026.100363_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104451","article-title":"Future potential therapeutics to treat MASH","volume":"30","author":"Mahajan","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.dmd.2026.100363_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1433857","article-title":"Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases","volume":"12","author":"Sandireddy","year":"2024","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100363_bib6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.chom.2016.10.016","article-title":"The liver at the nexus of host-microbial interactions","volume":"20","author":"Macpherson","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"5","key":"10.1016\/j.dmd.2026.100363_bib7","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s11427-023-2353-0","article-title":"Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis","volume":"67","author":"Jia","year":"2024","journal-title":"Sci China Life Sci"},{"issue":"11","key":"10.1016\/j.dmd.2026.100363_bib8","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1007\/s11427-019-1563-3","article-title":"Regulation of glucose and lipid metabolism in health and disease","volume":"62","author":"Chen","year":"2019","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.dmd.2026.100363_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123211","article-title":"Metabolic disorders, inter-organ crosstalk, and inflammation in the progression of metabolic dysfunction-associated steatotic liver disease","volume":"359","author":"Wang","year":"2024","journal-title":"Life Sci"},{"issue":"7","key":"10.1016\/j.dmd.2026.100363_bib10","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1021\/acs.molpharmaceut.8b00159","article-title":"Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in human liver","volume":"15","author":"Jamwal","year":"2018","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1016\/j.dmd.2026.100363_bib11","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1101\/gr.103341.109","article-title":"Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver","volume":"20","author":"Yang","year":"2010","journal-title":"Genome Res"},{"issue":"11","key":"10.1016\/j.dmd.2026.100363_bib12","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40262-019-00783-z","article-title":"Phenotyping of human CYP450 enzymes by endobiotics: current knowledge and methodological approaches","volume":"58","author":"Magliocco","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.dmd.2026.100363_bib13","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/dmd.115.065979","article-title":"CYP3A activity and expression in nonalcoholic fatty liver disease","volume":"43","author":"Woolsey","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100363_bib14","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s41467-023-37209-1","article-title":"Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease","volume":"14","author":"Powell","year":"2023","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.dmd.2026.100363_bib15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.clinre.2011.04.015","article-title":"Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role","volume":"35","author":"Aubert","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100363_bib16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ptr.7604","article-title":"Transcriptomics and metabolomics reveal the role of CYP1A2 in psoralen\/isopsoralen-induced metabolic activation and hepatotoxicity","volume":"37","author":"Zhang","year":"2023","journal-title":"Phytother Res"},{"issue":"8","key":"10.1016\/j.dmd.2026.100363_bib17","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1124\/dmd.122.001011","article-title":"Cytochrome P450 and other drug-metabolizing enzymes as therapeutic targets","volume":"51","author":"Foti","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2026.100363_bib18","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100363_bib19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1006\/abbi.2001.2499","article-title":"Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity","volume":"393","author":"Rodriguez-Antona","year":"2001","journal-title":"Arch Biochem Biophys"},{"issue":"9","key":"10.1016\/j.dmd.2026.100363_bib20","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1124\/dmd.121.000438","article-title":"Silybin restored CYP3A expression through the sirtuin 2\/nuclear factor kappa-B pathway in mouse nonalcoholic fatty liver disease","volume":"49","author":"Zhang","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100363_bib21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41401-022-00924-4","article-title":"Silybin regulates P450s activity by attenuating endoplasmic reticulum stress in mouse nonalcoholic fatty liver disease","volume":"44","author":"Wu","year":"2023","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"10.1016\/j.dmd.2026.100363_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.apsb.2019.11.002","article-title":"Cytochrome P450 endoplasmic reticulum-associated degradation (ERAD): therapeutic and pathophysiological implications","volume":"10","author":"Kwon","year":"2020","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"10.1016\/j.dmd.2026.100363_bib23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/03602532.2016.1195403","article-title":"Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame","volume":"48","author":"Kim","year":"2016","journal-title":"Drug Metab Rev"},{"issue":"6","key":"10.1016\/j.dmd.2026.100363_bib24","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1074\/jbc.M114.611525","article-title":"Human liver cytochrome P450 3A4 ubiquitination: molecular recognition by UBC7-gp78 autocrine motility factor receptor and UbcH5a-CHIP-Hsc70-Hsp40 E2-E3 ubiquitin ligase complexes","volume":"290","author":"Wang","year":"2015","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.dmd.2026.100363_bib25","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1074\/jbc.M110.186981","article-title":"Liver cytochrome P450 3A endoplasmic reticulum-associated degradation: a major role for the p97 AAA ATPase in cytochrome P450 3A extraction into the cytosol","volume":"286","author":"Acharya","year":"2011","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.dmd.2026.100363_bib26","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.apsb.2025.01.010","article-title":"The ubiquitin-proteasome system: a potential target for the MASLD","volume":"15","author":"Liu","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.dmd.2026.100363_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102043","article-title":"Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1\/PPARgamma binodal complementary modules","volume":"45","author":"Das","year":"2021","journal-title":"Redox Biol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100363_bib28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/mc.20632","article-title":"Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas","volume":"50","author":"Matsuyama","year":"2011","journal-title":"Mol Carcinog"},{"issue":"22","key":"10.1016\/j.dmd.2026.100363_bib29","doi-asserted-by":"crossref","first-page":"14208","DOI":"10.1021\/acsomega.1c00894","article-title":"Proteomic analysis reveals that metformin suppresses PSMD2, STIP1, and CAP1 for preventing gastric cancer AGS cell proliferation and migration","volume":"6","author":"Wang","year":"2021","journal-title":"ACS Omega"},{"issue":"3","key":"10.1016\/j.dmd.2026.100363_bib30","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1007\/s00210-025-04729-0","article-title":"Integrated bioinformatics and molecular docking identify CCNB1, CDK1, and CYP1A2 as therapeutic targets of phytochemicals in hepatocellular carcinoma","volume":"399","author":"Isiyel","year":"2026","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100363_bib31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/cpt.3643","article-title":"Hepatic impairment and the differential effects on drug clearance mechanisms: analysis of pharmacokinetic changes in disease state","volume":"118","author":"Tang","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100363_bib32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/03602530903286476","article-title":"Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2","volume":"42","author":"Zhou","year":"2010","journal-title":"Drug Metab Rev"},{"issue":"3","key":"10.1016\/j.dmd.2026.100363_bib33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1208\/s12248-009-9127-y","article-title":"Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2","volume":"11","author":"Zhou","year":"2009","journal-title":"AAPS J"},{"key":"10.1016\/j.dmd.2026.100363_bib34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev-biochem-060410-150257","article-title":"Molecular architecture and assembly of the eukaryotic proteasome","volume":"82(1)","author":"Tomko","year":"2013","journal-title":"Annu Rev Biochem"},{"issue":"4","key":"10.1016\/j.dmd.2026.100363_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2026.111334","article-title":"Plasticity in the structure and assembly of proteasomes","volume":"302","author":"Chang","year":"2026","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.dmd.2026.100363_bib36","article-title":"Expression of PSMD2 gene in hepatocellular carcinoma and its correlation with immune checkpoints and prognosis","volume":"15","author":"Gu","year":"2025","journal-title":"Sci Rep"},{"issue":"22","key":"10.1016\/j.dmd.2026.100363_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e40117","article-title":"Identification of PSMD2 as a promising biomarker for pancreatic cancer patients based on comprehensive bioinformatics and in vitro studies","volume":"10","author":"Feng","year":"2024","journal-title":"Heliyon"},{"issue":"49","key":"10.1016\/j.dmd.2026.100363_bib38","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1038\/s41388-023-02866-5","article-title":"Dual network analysis of transcriptome data for discovery of new therapeutic targets in non-small cell lung cancer","volume":"42","author":"Bai","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.dmd.2026.100363_bib39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.canlet.2018.05.018","article-title":"PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation","volume":"430","author":"Li","year":"2018","journal-title":"Cancer Lett"},{"issue":"22","key":"10.1016\/j.dmd.2026.100363_bib40","doi-asserted-by":"crossref","first-page":"24882","DOI":"10.18632\/aging.203722","article-title":"Prognostic and immune infiltration signatures of proteasome 26S subunit, non-ATPase (PSMD) family genes in breast cancer patients","volume":"13","author":"Xuan","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"10.1016\/j.dmd.2026.100363_bib41","doi-asserted-by":"crossref","first-page":"902","DOI":"10.3390\/cancers12040902","article-title":"Drug development targeting the ubiquitin-proteasome system (UPS) for the treatment of human cancers","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dmd.2026.100363_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123125","article-title":"Bortezomib in cancer therapy: mechanisms, side effects, and future proteasome inhibitors","volume":"358","author":"Sogbein","year":"2024","journal-title":"Life Sci"},{"key":"10.1016\/j.dmd.2026.100363_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101231","article-title":"Liver fibrosis in NAFLD\/NASH: from pathophysiology towards diagnostic and therapeutic strategies","volume":"95","author":"Parola","year":"2024","journal-title":"Mol Aspects Med"},{"issue":"3","key":"10.1016\/j.dmd.2026.100363_bib44","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s11427-025-3100-1","article-title":"Deubiquitinases in liver diseases: from mechanisms to targeted therapy","volume":"69","author":"Zhang","year":"2026","journal-title":"Sci China Life Sci"},{"issue":"1","key":"10.1016\/j.dmd.2026.100363_bib45","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s12967-025-06255-2","article-title":"The emerging role of E3 ubiquitin ligases and deubiquitinases in metabolic dysfunction-associated steatotic liver disease","volume":"23","author":"Zhang","year":"2025","journal-title":"J Transl Med"},{"issue":"19","key":"10.1016\/j.dmd.2026.100363_bib46","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.7150\/thno.28676","article-title":"Small heterodimer partner regulates circadian cytochromes P450 and drug-induced hepatotoxicity","volume":"8","author":"Zhang","year":"2018","journal-title":"Theranostics"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562600632X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562600632X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:54:07Z","timestamp":1791996847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562600632X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S009095562600632X"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100363","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMD2 mediates the degradation of CYP1A2 and promotes the progression of metabolic dysfunction-associated steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100363","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100363"}}